Exchange: NASDAQ·Updated 10:05 AM EST

LKFT News

News
all
press releases
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
More News
Lakefront Biotherapeutics - Sponsored ADR (LKFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...
Benzinga
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.read more...
Benzinga
Keymed Biosciences Announces 2026 H1 Results and Business Updates Keymed Biosciences Announces 2026 H1 Results and Business Updates PR Newswire CHENGDU, China, Aug. 20, 2026 CHENGDU, China, Aug. 20, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim...
PR Newswire
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia...
Business Wire

Advertisement|Remove ads.